Proficio Capital Partners LLC Buys Shares of 29,894 Bio-Rad Laboratories, Inc. (NYSE:BIO)

Proficio Capital Partners LLC bought a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 29,894 shares of the medical research company’s stock, valued at approximately $9,820,000. Proficio Capital Partners LLC owned 0.11% of Bio-Rad Laboratories as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in BIO. Venturi Wealth Management LLC increased its position in Bio-Rad Laboratories by 2,175.0% during the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 87 shares during the period. Gladius Capital Management LP acquired a new stake in shares of Bio-Rad Laboratories during the 3rd quarter worth approximately $32,000. Asset Planning Inc acquired a new stake in shares of Bio-Rad Laboratories during the 4th quarter worth approximately $33,000. UMB Bank n.a. grew its position in shares of Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock worth $36,000 after buying an additional 32 shares during the period. Finally, Cape Investment Advisory Inc. acquired a new stake in shares of Bio-Rad Laboratories during the 4th quarter worth approximately $38,000. Institutional investors and hedge funds own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Performance

NYSE BIO opened at $255.34 on Friday. The company has a fifty day simple moving average of $311.97 and a 200 day simple moving average of $328.01. Bio-Rad Laboratories, Inc. has a 12-month low of $244.00 and a 12-month high of $387.99. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. The company has a market cap of $7.15 billion, a P/E ratio of -3.93 and a beta of 0.99.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Sell-side analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on the stock. StockNews.com downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Wells Fargo & Company reduced their price objective on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $395.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.